1P-LSD

1P-LSD (1-propanoyl-lysergic acid diethylamide) is a psychedelic drug of the lysergamide class that is a derivative and functional analogue of LSD and a homologue of ALD-52. It originated in 2015 when it appeared a designer drug sold online. It modifies the LSD molecule by adding a propionyl group to the nitrogen molecule of LSD's indole group.

Pharmacology
Like ALD-52, 1P-LSD is believed to act as prodrug for LSD via hydrolysis of the propionyl group. When 1P-LSD is incubated in human serum, administered intravenously to rats, or administered either orally or intravenously to human subjects, high levels of LSD and relatively low levels of 1P-LSD are quickly detected, demonstrating that 1P-LSD is rapidly hydrolyzed into LSD in vivo following ingestion. Indeed, following intravenous administration in humans 1P-LSD is detectable in serum for no longer than 4 hours, after which it is completely converted to LSD. These findings are supported by the similar duration and behavioral effects of 1P-LSD and LSD in both animal and human experiments.

Effects


The subjective effects of 1P-LSD are not well defined in the scientific literature, although they are generally thought to be comparable to that of LSD. In a 2020 study, the qualitative effects of 1P-LSD and LSD were similar when measured using visual analog scales.

Legal status
As of 2015, 1P-LSD is unscheduled in the United States and Canada, but may be considered illegal if sold or used for human consumption as a structural analog of LSD under the Federal Analogue Act in the US. 1P-LSD is a prohibited or controlled substance in Australia, France, Finland, Denmark, Germany, Estonia, Japan, Latvia, Norway, Romania, Sweden, Switzerland, United Kingdom, Italy, Singapore, the Czech Republic, and Croatia. 1P-LSD has been illegal in Russia since 2017 as an LSD derivative.